Beyond viral vectors: an end-to-end platform for rapid CAR-T and CAR-NK generation

Tuesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Beyond viral vectors: an end-to-end platform for rapid CAR-T and CAR-NK generation

This webinar presents a non-viral workflow spanning plasmid engineering, mRNA optimization, production, purification, and immune cell engineering, which offers an alternative to lentiviral vectors for generating CAR-T and CAR-NK cells, using transient mRNA-based engineering to shorten iteration cycles and speed the evaluation of new CAR constructs.

Attendees will see supporting data on mRNA quality, delivery efficiency, and cytotoxic function, alongside a framework for deciding when transient, non-viral modification is the right approach.

Attend this webinar to learn about:

Generating a sequence-verified CD19 CAR mRNA plasmid in 4 weeks through an integrated design and DNA assembly workflow
Producing 90-95% capped mRNA with process-related impurities below the limit of detection using monolith purification, polishing, and at-line analytics
CAR expression from preformed-vesicle delivery, reaching 87% in primary T cells (vs 26% with a standard LNP kit) and 60% in primary NK cells
Cytotoxicity data showing up to 90% killing of CD19-positive tumor cells by CAR-T cells and 69% killing by CAR-NK cells

Claire Gueguen, PhD

R&D Life Sciences Manager at Sartorius

Dr Claire Guéguen is R&D Life Sciences Manager at Sartorius Polyplus. After obtaining her PhD in Immunology, she worked for five years at Adaptimmune in the R&D Department on TCR T-cell therapies and on the generation of allogeneic T cells from iPSCs. She now oversees the screening and the development of innovative transfection reagents for in vitro and in vivo nucleic acid delivery, including the transfection of immune and stems cells.

Rok Sekirnik, PhD

Head Process Development for mRNA and pDNA at Sartorius

Rok Sekirnik completed his PhD at Oxford University. He has worked in the areas of mAb, vaccine, and gene therapy vector development. His team at Sartorius BIA Separations is focused on developing high-yielding, cost-effective purification approaches for pDNA and mRNA production.

In 26 Days

You have registered for this webinar